摘要
造血干细胞移植是治疗多发性骨髓瘤有效方法,特别是可作为初次缓解后的巩固治疗手段,也可用于复发/难治患者挽救治疗。新药虽然改善了多发性骨髓瘤患者的预后,但仍然不能替代造血干细胞移植。自体干细胞移植仍是目前推荐的首选移植方式。它可延长多发性骨髓瘤患者生存,但不能彻底治愈疾病。异基因干细胞移植是目前唯一有可能治愈骨髓瘤的方法,但移植后疾病复发及较高的相关死亡率抵消了其可能带来的收益,目前仅推荐作为高危年轻患者的治疗方式。
New drugs improved prognosis of patients with multiple myeloma （MM）, however it could not replace hematopoietic stem cell transplantation （HSCT） for MM. HSCT was effective to treat MM, which could be used as consolidation treatment in relapse or new diagnosed patients. Autologous HSCT was most frequently used, which could prolong survival time of MM patients, however it was not able to cure this disease. AIIologous HSCT was potentially able to cure multiple myeloma, but death rate of transplantation was high and it need to improve AIIologous HSCT. At present, allologous HSCT was only recommended for young patients with high risk MM.
出处
《临床药物治疗杂志》
2013年第6期38-42,共5页
Clinical Medication Journal
基金
国家自然科学基金(81172252)
首都临床特色应用研究专项资助课题(Z131107002213146)
关键词
多发性骨髓瘤
造血干细胞移植
治疗
Multiple myeloma
Hematopoietic cell transplantation
Treatment
